Skip to content

An international Delphi consensus for reporting of setting in psychedelic clinical trials

Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman, ReSPCT Experts

Universität Zürich, ZORA July 1, 2025 DOI: 10.5167/uzh-284344 via OpenAlex

Summary

AI-generated from the abstract

An international Delphi consensus study involving 89 experts from 17 countries generated guidelines for reporting contextual variables in psychedelic clinical research. Over four rounds, 770 responses were synthesized into 49 items, with 30 reaching consensus as important or very important for at least 70% of experts. These items form the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, covering physical environment, dosing session procedure, therapeutic framework and protocol, and subjective experiences. The findings reveal significant ambiguities in current conceptualizations of set and setting, and the guidelines provide a new standard for documenting extra-pharmacological factors in psychedelic research.

Study at a glance

Characteristics Delphi consensus study Peer reviewed
Sample size 89
Population Psychedelic researchers, clinicians and past trial participants from 17 countries
Keywords Delphi method Clinical trial Session web analytics Documentation Test biology
Key finding The Delphi process yielded 30 extra-pharmacological variables that reached predefined consensus ratings, forming the ReSPCT guidelines for reporting settings in psychedelic clinical trials.

Abstract

Psychedelic substances exhibit complex interactions with the 'set and setting' of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables' known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based guidelines for reporting settings in psychedelic clinical research, according to an international group of psychedelic researchers, clinicians and past trial participants. We conducted a Delphi consensus study composed of four iterative rounds of quasi-anonymous online surveys. A total of 89 experts from 17 countries independently listed potentially important psychedelic setting variables. There were 770 responses, synthesized into 49 distinct items that were subsequently rated, debated and refined. The process yielded 30 extra-pharmacological variables reaching predefined consensus ratings:i.e., 'important' or 'very important' for ≥70% of experts. These items compose the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, categorized into physical environment, dosing session procedure, therapeutic framework and protocol, and subjective experiences. Emergent findings reveal significant ambiguities in current conceptualizations of set and setting. The ReSPCT guidelines and accompanying explanatory document provide a new standard for the design and documentation of extra-pharmacological variables in psychedelic clinical research.

Comments

No comments yet.

Log in to comment